User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

Interactions with Platform & by Email *

INTERACTIONS

Unique # Participated *

PARTICIPANTS

Responses Validated *

VALIDATIONS

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Respiratory Diseases – Common and Serious.....II-1
Rhinoviruses – Root Cause of Major Respiratory Diseases.....II-1
1$100
   Leading Asthmatic Drugs and their Patent Expiries.....II-2
Antihistamine or Allergic Rhinitis Market.....II-2
1$100
   Leading Anti-Allergy Drugs and Patent Expiry Years.....II-3
Current and Future Analysis.....II-3
Regional Perspective.....II-3
Product Segment Perspective.....II-3
1$100
   Influenza.....II-4
Asthma.....II-4
1$100
   Factors Promoting Asthma.....II-5
Treatment.....II-5
Respiratory Distress Syndrome (RDS).....II-5
1$100
   Symptoms.....II-6
Complications Related to RDS.....II-6
Analysis of RDS.....II-6
1$100
   Alternative Methods for the Treatment of RDS.....II-7
Preventive Measures.....II-7
1$100
   Chronic Obstructive Pulmonary Disease.....II-8
Characteristics and Symptoms of COPD.....II-8
Risks Associated with COPD.....II-8
1$100
   Bronchitis.....II-9
Respiratory Syncytial Virus (RSV).....II-9
1$100
   Respiratory Therapy with Information Technology.....II-10
Antiviral Drugs for Controlling Influenza and RSV Infections.....II-10
Pulmonary Drug Delivery.....II-10
Why are Lungs Considered a Good Alternative?.....II-10
1$100
   COPD – Taking a Toll on Human Lives.....II-11
Upper Respiratory Tract Infections (URIs).....II-11
Respiratory Failure Management.....II-11
1$100
   CPAP: Non-Invasive Respiration.....II-12
Face Masks: Carriers of Oxygen Therapy.....II-12
Endotracheal Intubation and Ventilatory Support.....II-12
1$100
   Endotracheal Intubation Turns Perilous.....II-13
Ventilator Strategy.....II-13
1$100
   Methods of Ventilation.....II-141$100
   Weaning from the Ventilator.....II-15
Respiratory Support: A Broader Perspective.....II-15
Humidification.....II-15
Posture.....II-15
Physiotherapy.....II-15
Pharmacological Adjuncts.....II-15
1$100
   Sedation.....II-16
New Drugs, Treatments Ease Life of Patients with Respiratory Problems.....II-16
Progesterone.....II-16
1$100
   Partial Liquid Ventilation.....II-17
Heliox.....II-17
1$100
   High-level PREP.....II-18
Respiratory Failure.....II-18
1$100
   Types of Respiratory Failure.....II-19
Factors Leading to Respiratory Failure.....II-19
Blockage of air passage.....II-19
Drug abuse or alcohol addiction.....II-19
Obesity.....II-19
Muscle weakness.....II-19
Lung disorders and diseases.....II-19
Abnormalities in Chest Walls.....II-19
Cellular Disorders.....II-19
1$100
   Treatment for Respiratory Failure.....II-20
Role of Health Care Teams.....II-20
1$100
   Long-Term Consequences of Respiratory Failures.....II-21
Preventive Measures.....II-21
Measures to Prevent the Recurrence of Respiratory Diseases.....II-21
Telithromycin: Treatment for Respiratory Disorders.....II-21
1$100
   Consequences of Telithromycin.....II-22
1$100
   Arcadia Resources, Inc Acquires Remedy Therapeutics, L.L.C.....II-23
Sirna Forms Alliance with GlaxoSmithKline.....II-23
Pharmaxis Ltd and Nigaard Pharma Enters into Distribution Agreement.....II-23
Teva Regains Leadership Position through Ivax Acquisition.....II-23
1$100
   AstraZeneca Submits Symbicort for US FDA Approval.....II-24
Ranbaxy Laboratories Receives FDA Approval.....II-24
Innovata Inks Development Agreement for Duohaler.....II-24
Novartis Obtains License from Arrow Therapeutics for A60444 Molecule
  Inhibitor.....II-24
1$100
   Arakis Ltd and Vectura Group plc Initiate Phase IIb Clinical Trial of NVA237.....II-25
Schering-Plough Receives FDA Approval for Asmanex.....II-25
Isis Pharmaceuticals Develops ISIS 369645.....II-25
Inyx Acquires Celltech Manufacturing Services from UCB.....II-25
Ashton Pharmaceuticals Partners with Innovata and Merck.....II-25
1$100
   King Pharmaceuticals Collaborates with Inyx.....II-26
Inyx Pharma Ltd. Bags a Contract from Generics.....II-26
1$100
   Alnylam Pharmaceuticals Initiates Phase I Trials on ALN-RSV01.....II-27
MAP and Elan Extend their Agreement for Developing Advanced Version of Asthma
  Drug.....II-27
Accentia Enters into Licensing Agreement with Collegium.....II-27
1$100
   Novartis Inks Agreement with Arakis and Vectura.....II-28
Pfizer and Rigel Sign Collaborative Agreement.....II-28
1$100
   NicOx Enters into Developing and Licensing Agreement with Topigen.....II-29
Merck to Strike a Licensing Deal with Innovata for Developing Respiratory
  Medicines.....II-29
1$100
   Lannett Receives Approval from FDA for the Distribution of Terbutaline Sulfate
  Tablets.....II-30
GlaxoSmithKline Licenses Inhaled Respiratory Therapy from Theravance.....II-30
1$100
   Novartis’ Sandoz Completes Acquisition of Hexal AG.....II-31
Sandoz Acquires Eon Labs.....II-31
SkyePharma, PLC Enters into License Agreement with GlaxoSmithKline.....II-31
Kos Pharmaceuticals Signs Agreement with Aventis Pharmaceuticals.....II-31
US FDA Approves New Antibiotic, Ketek.....II-31
1$100
   Zambon Terminates Single-Agent Inhaler Project.....II-32
Boehringer Ingelheim Pharmaceuticals Obtains FDA Approval for Atrovent HFA.....II-32
Ranbaxy Receives FDA Approval for Loratadine and Pseudoephedrine Sulfate
  Tablets.....II-32
Lincoln Pharmaceuticals Limited Introduces Gatilink, an Antibiotic.....II-32
1$100
   GlaxoSmithKline Forms Alliance with Theravance.....II-33
Etiologics Acquires Bayer’s Pre-clinical Respiratory Research Group.....II-33
IVAX Pharmaceutical Signs Pan-European Agreement with 3M.....II-33
GlaxoSmithKline Inks Agreement with Theravance.....II-33
Cadila Pharmaceuticals Ltd Launches Montelast for Asthma.....II-33
Alpharma Unveils Generic Loratadine Syrup.....II-33
Dr. Reddy’s Laboratories Launches Brancho-Vaxom.....II-33
1$100
   Accentia Biopharmaceuticals, Inc. (US).....II-34
Aerogen, Inc. (US).....II-34
Aerovance, Inc (US).....II-34
airPharma (US).....II-34
1$100
   AstraZeneca (UK).....II-35
Aventis Pharma Limited (India).....II-35
Bespak (UK).....II-35
Boehringer Ingelheim Pharmaceuticals, Inc (Germany).....II-35
Cadila Pharmaceuticals (India).....II-35
1$100
   Dr. Reddy's Laboratories (India).....II-36
EvoGenix (Australia).....II-36
1$100
   GlaxoSmithKline (US).....II-37
GlaxoSmithKline Pharmaceuticals Ltd. (India).....II-37
Inyx, Inc. (US).....II-37
The Merck Generics Group (Germany).....II-37
1$100
   Novartis AG (Switzerland).....II-38
Pfizer, Inc. (US).....II-38
1$100
   Ranbaxy Laboratories Limited (India).....II-391$100
   Respironics, Inc (US).....II-40
Sandoz International GmbH (Germany).....II-40
1$100
   Schering-Plough Corp (US).....II-41
1$100
   Table 1: Recent Past, Current and Future Analysis for Respiratory Drugs by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....II-42

Table 2: World 10-Year Perspective for Respiratory Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....II-42
1$300
   Table 3: World Recent Past, Current and Future Analysis for Asthma Drugs by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....II-43

Table 4: World 10-Year Perspective for Asthma Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....II-43
1$300
   Table 5: World Recent Past, Current and Future Analysis for Allergic Rhinitis Drugs by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....II-44

Table 6: World 10-Year Perspective for Allergic Rhinitis Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....II-44
1$300
   Table 7: World Recent Past, Current and Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Drugs by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....II-45

Table 8: World 10-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....II-45
1$300
   A. Market Analysis.....III-1
Current & Future Analysis.....III-1
Market Scenario.....III-1
Asthma.....III-1
1$75
   COPD.....III-2
Leading Respiratory Drug Brands.....III-2
Strategic Corporate Developments.....III-2
6$450
   Focus on Select Players.....III-83$225
   B. Market Analytics.....III-11
Table 9: US Recent Past, Current and Future Analysis for Respiratory Drugs by Product Segment – Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....III-11

Table 10: US 10-Year Perspective for Respiratory Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....III-11
1$150
   Market Analysis.....III-12
Table 11: Canadian Recent Past, Current and Future Analysis for Respiratory Drugs by Product Segment – Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....III-12
1$150
   Table 12: Canadian 10-Year Perspective for Respiratory Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....III-13
1$150
   Market Analysis.....III-14
Table 13: Japanese Recent Past, Current and Future Analysis for Respiratory Drugs by Product Segment – Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....III-14
1$150
   Table 14: Japanese 10-Year Perspective for Respiratory Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....III-15
1$150
   A. Market Analysis.....III-16
Current & Future Analysis.....III-16
Strategic Corporate Developments.....III-16
4$300
   Focus on Select Players.....III-203$225
   B. Market Analytics.....III-23
Table 15: European Recent Past, Current and Future Analysis for Respiratory Drugs by Product Segment – Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....III-23

Table 16: European 10-Year Perspective for Respiratory Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....III-23
1$150
   A. Market Analysis.....III-24
Current & Future Analysis.....III-24
Strategic Corporate Developments.....III-24
1$75
   Focus on Select Players.....III-254$300
   B. Market Analytics.....III-29
Table 17: Rest of World Recent Past, Current and Future Analysis for Respiratory Drugs by Product Segment – Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....III-29

Table 18: Rest of World 10-Year Perspective for Respiratory Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....III-29
1$150